Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery

Biochemical and Biophysical Research Communications

Volumn 311, Issue 4, 2003, Pages 822-828

  Benouchan, Malika ^a   Do Nascimento, Filipe ^a   Sebbah Louriki, Malika ^a   Salzmann, Jean Loup ^a   Crépin, Michel ^a,b   Perret, Gérard Y ^a   Colombo, Bruno M ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Apoptosis; Bystander effect; Cationic lipids; Cell cell interactions; Endothelial cells; Gene therapy; Melanoma; Nitroreductase; Three dimensional cocultures

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; NITROREDUCTASE; PRODRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL DEATH; CELL KILLING; CELL SPREADING; CONTROLLED STUDY; ENDOTHELIUM CELL; ESCHERICHIA COLI; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; MELANOMA B16; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR VASCULARIZATION; UMBILICAL VEIN;

ESCHERICHIA COLI; MURINAE;

EID: 0242437993     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.10.068     Document Type: Article

References (35)

1. Ramachandran C., Melnick S.J. Multidrug resistance in human tumors - molecular diagnosis and clinical significance. Mol. Diagn. 4:1999;81-94.
2. Maehara Y., Kakeji Y., Oda S., Baba H., Sugimachi K. Tumor growth patterns and biological characteristics of early gastric carcinoma. Oncology. 61:2001;102-112.
3. Christmann M., Pick M., Lage H., Schadendorf D., Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int. J. Cancer. 92:2001;123-129.
4. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res. Rev. 35:2001;161-204.
5. Paley P.J. Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies. Curr. Oncol. Rep. 4:2002;165-174.
6. van Hattum A.H., Hoogsteen I.J., Schluper H.M., Maliepaard M., Scheffer G.L., Scheper R.J., Kohlhagen G., Pommier Y., Pinedo H.M., Boven E. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. Br. J. Cancer. 87:2002;665-672.
7. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
8. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
9. Heissig B., Hattori K., Friedrich M., Rafii S., Werb Z. Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr. Opin. Hematol. 10:2003;136-141.
10. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:2000;203-212.
11. Brekken R.A., Overholser J.P., Stastny V.A., Waltenberger J., Minna J.D., Thorpe P.E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60:2000;5117-5124.
12. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C., Perricaudet M., Yeh P., Lu H. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. USA. 95:1998;6367-6372.
13. Hajitou A., Sounni N.E., Devy L., Grignet-Debrus C., Lewalle J.M., Li H., Deroanne C.F., Lu H., Colige A., Nusgens B.V., Frankenne F., Maron A., Yeh P., Perricaudet M., Chang Y., Soria C., Calberg-Bacq C.M., Foidart J.M., Noel A. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res. 61:2001;3450-3457.
14. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
15. Greco O., Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell Physiol. 187:2001;22-36.
16. Denny W.A. Nitroreductase-based GDEPT. Curr. Pharm. Des. 8:2002;1349-1361.
17. Chen L., Waxman D.J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des. 8:2002;1405-1416.
18. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L., Abraham G.N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274-5283.
19. Bi W.L., Parysek L.M., Warnick R., Stambrook P.J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4:1993;725-731.
20. Barba D., Hardin J., Sadelain M., Gage F.H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA. 91:1994;4348-4352.
21. Colombo B.M., Benedetti S., Ottolenghi S., Mora M., Pollo B., Poli G., Finocchiaro G. The bystander effect: association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. 6:1995;763-772.
22. Beaupain R. A method for three-dimensional coculture of cancer cells combined to any other type of cells maintained organotypically. Methods Cell Sci. 21:1999;25-30.
23. Fillat C., Carrio M., Cascante A., Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr. Gene Ther. 3:2003;13-26.
24. Bridgewater J.A., Knox R.J., Pitts J.D., Collins M.K., Springer C.J. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 8:1997;709-717.
25. Wilson W.R., Pullen S.M., Hogg A., Helsby N.A., Hicks K.O., Denny W.A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 62:2002;1425-1432.
26. Graham C.K., Kobayashi H., Stankiewicz K.S., Man S., Kapitain S.J., Kerbel R.S. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J. Natl. Cancer Inst. 86:1994;975-982.
27. dit Faute M.A., Laurent L., Ploton D., Poupon M.F., Jardillier J.C., Bobichon H. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin. Exp. Metastasis. 19:2002;161-168.
28. Korff T., Kimmina S., Martiny-Baron G., Augustin H.G. Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J. 15:2001;447-457.
29. Kan O., Griffiths L., Baban D., Iqball S., Uden M., Spearman H., Slingsby J., Price T., Esapa M., Kingsman S., Kingsman A., Slade A., Naylor S. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther. 8:2001;473-482.
30. Mesnil M., Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 60:2000;3989-3999.
31. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:1997;964-967.
32. Masuda H., Asahara T. Post-natal endothelial progenitor cells for neovascularization in tissue regeneration. Cardiovasc. Res. 58:2003;390-398.
33. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., Kearne M., Magner M., Isner J.M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85:1999;221-228.
34. De Palma M., Venneri M.A., Roca C., Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9:2003;789-795.
35. Koizumi K., Tsutsumi Y., Kamada H., Yoshioka Y., Watanabe M., Yamamoto Y., Okamoto T., Mukai Y., Nakagawa S., Tani Y., Mayumi T. Incorporation of adult organ-derived endothelial cells into tumor blood vessel. Biochem. Biophys. Res. Commun. 306:2003;219-224.